key: cord-0893071-mm7u0dcy
authors: Ngai, Hoi Wa; Kim, Dae Hong; Hammad, Mohamed; Gutova, Margarita; Aboody, Karen; Cox, Christopher D.
title: Stem Cell‐based therapies for COVID‐19‐related acute respiratory distress syndrome
date: 2022-04-14
journal: J Cell Mol Med
DOI: 10.1111/jcmm.17265
sha: 219542f3c255ca423f34adff44c01333711a9af2
doc_id: 893071
cord_uid: mm7u0dcy

As the number of confirmed cases and resulting death toll of the COVID‐19 pandemic continue to increase around the globe ‐ especially with the emergence of new mutations of the SARS‐CoV‐2 virus in addition to the known alpha, beta, gamma, delta and omicron variants ‐ tremendous efforts continue to be dedicated to the development of interventive therapeutics to mitigate infective symptoms or post‐viral sequelae in individuals for which vaccines are not accessible, viable or effective in the prevention of illness. Many of these investigations aim to target the associated acute respiratory distress syndrome, or ARDS, which induces damage to lung epithelia and other physiologic systems and is associated with progression in severe cases. Recently, stem cell‐based therapies have demonstrated preliminary efficacy against ARDS based on a number of preclinical and preliminary human safety studies, and based on promising outcomes are now being evaluated in phase II clinical trials for ARDS. A number of candidate stem cell therapies have been found to exhibit low immunogenicity, coupled with inherent tropism to injury sites. In recent studies, these have demonstrated the ability to modulate suppression of pro‐inflammatory cytokine signals such as those characterizing COVID‐19‐associated ARDS. Present translational studies are aiming to optimize the safety, efficacy and delivery to fully validate stem cell‐based strategies targeting COVID‐19 associated ARDS for viable clinical application.

distinct strain of coronavirus related to those that resulted in the severe acute respiratory syndrome (SARS) pandemic in 2003 and the Middle East respiratory syndrome (MERS) pandemic in 2012. 3 Because of its recent emergence, much remains to be elucidated regarding the pathophysiological mechanisms, sequelae and strength and duration of the host immune response in SARS-CoV-2, despite a tremendous amount of research worldwide. SARS-CoV-2 has demonstrated high genetic variability and a rapid mutation rate, and preliminary evidence suggests that immune protection may be limited, providing challenges to the development of vaccines and treatments. 4 The persistent emergence of novel SARS-Cov-2 variants, during COVID-19-related pneumonia, with the subset of patients progressing to ARDS exhibiting a mortality rate of 52.4%. 7 With a median patient age of 51, this case study also underscored the elevated susceptibility of older subpopulation to ARDS and consequently a substantially higher risk of mortality. ARDS is a lifethreatening lung pathology characterized by rapid onset and resulting from a massive and generalized pro-inflammatory immune response in the lungs, circulation and other tissues in patients; this cytokine storm represents the most life-threatening development in COVID-19 patients. 8 In non-COVID patients, ARDS typically arises as a complication of pneumonia, systemic infection and major trauma, 9 and it is associated with elevated transport of fluid from lung capillaries to alveoli, 10 the air sacs that are the site of gas exchange with the blood, resulting in pulmonary oedema, hypoxemia, and loss of lung compliance secondary to epithelial damage and pulmonary fibrosis.

The cytokine storm characterizing COVID-19 ARDS has also been implicated in tissue damage and embolus formation in multiple organ systems and to play a key role in the pathophysiology of extrapulmonary multiple organ failure secondary to ARDS 11,12 ; indeed, this process is hypothesized to be key in the development of a number of emergent chronic post-COVID-19 pathologies. For instance, emerging evidence investigating the development of 'postviral syndrome' in a subset of post-recovery COVID-19 patients is examining possible corollaries with earlier SARS variants which produced a chronic pathological state resembling chronic fatigue/myalgic encephalomyelitis as a result of viral infiltration to select brain regions. 13, 14 Histopathological examination of brain tissue in necropsied patients has also demonstrated neurological complications in a subset of COVID-19 patients implicating non-inflammatory neurovascular damage in clinical manifestations ranging from loss of olfaction/gustation to loss of involuntary control of breathing through medullary centres, with the virus hypothesized to spread to the brain from the upper respiratory tract via the transcribrial route, where angiotensin-converting enzyme 2 (ACE2)-expressing tissues enable viral internalization. 15 Evidence from other coronaviruses in human case reports and in vivo models also suggest the possibility of brain lesioning and fatal encephalitis. 16 ized mortality rates as high as 17% 24 and was noted for mutating to optimize viral-host binding and replication 25 ; the Middle East respiratory syndrome (MERS-Cov) virus, with which SARS-Cov-2 shares 50% sequence homology 23 and which enters host cells via the DPP4 receptor, exhibits a mortality rate of 35%. 26, 27 Symptoms of the other human coronavirus strains are generally mild with low rates of mortality and morbidity and these infections are typically associated with the 'common cold', accounting for 10%-30% of all adult upper respiratory infections annually. 22 Coronaviruses are comprised of single-stranded, positive-sense RNA genomes of 28-32 kb in length, the largest genomes of all RNA viruses, and these are translated to non-structural proteins through two open-reading frames. 28 SARS-Cov-2 displays a surface Spike S glycoprotein on its viral envelope that is critical for host receptor binding 29 and invades host cells via interaction with the angiotensin-converting enzyme 2 (ACE2) receptor and is subsequently internalized where it integrates within the host genome and exploits its machinery for viral replication. ACE2 receptors are widely distributed in lung alveolar epithelia as well as nasopharyngeal and oral mucosa cells; extra-pulmonary expression is widely distributed among tissues spanning multiple physiological systems, however, including the liver, kidneys, gut, endothelial and vascular smooth muscle, and brain, providing a mechanism for multi-organ involvement. 30 

Despite years of efforts by multiple investigative teams aiming to develop viable treatments for ARDS, many candidate therapies have failed to show efficacy. 31 While corticosteroidal anti-inflammatory drugs such as dexamethasone and hydrocortisone [32] [33] [34] or interleukin receptor antagonists [35] [36] [37] [38] [39] have been investigated for ARDS and COVID-associated ARDS with evidence of success for severely ill/ ventilated patient outcomes in a large number of instances, study outcomes to date have also proven inconsistent with these interventions, with steroidal interventions in some cases even elevating mortality in related cases of ARDS with influenza, leading to hesitancy among many clinicians to rely on these-especially given the lack of clarity on risk factors in instances of contrainidication. 33 In the case of broad immuno-suppressant effects with cytokinesuppressant drugs for instance, it has been hypothesized that immunosuppression may worsen infection which in some cases outweighs the beneficial effects of cytokine storm suppression, depending on the stage of disease and pre-existing immune status of the patient.

More recently, certain stem cell-based therapies are beginning to show promising results in mitigating ARDS symptoms. Key examples of these candidate interventions are shown in Table 1 . These carry a number of predicted advantages over corticosteroidal or receptor antagonist-based pharmacological interventions, including their intrinsic inflammatory-suppressant properties which combine with a milieu of added supportive therapeutic components which promote for instance cellular repair and normalization of function; their generally non-immunogenic properties as the molecular contents are protected in physiological settings within lipid bilayers, eluding immune recognition; elevated uptake of their secretory components, as carried in extracellular vesicles owing to their recognition as biological carriers, optimizing delivery efficiency compared with non-cellular/non-vesicular molecular therapies; and the sustained secretion of therapeutically relevant factors following administration, which allows for a more protracted delivery within the recipient following each dose while simultaneously removing the need for higher and less well-tolerated single-dose concentrations within a single dose to achieve efficacy.

Mesenchymal stem cells (MSCs) have been given particular attention in recent years as they do not require de-differentiation as is the case with pluripotent sources, yet can still be induced to lineagespecific, directed differentiation. 40, 41 MSCs can bypass the technical constraints presented by isolating cells from specific organs, or ethical concerns surrounding use of embryonic cells because, they can be harvested from both autologous and allogeneic sources of relatively accessible tissue sources including umbilical cord, bone marrow, adipose tissue, and placenta. 42 

The initiating events for the progression of acute lung injury and 

High levels of pro-inflammatory cytokines, such as TNFα, TGFβ1, IL-1β, and IL-8, have been reported in pulmonary oedema fluid from ARDS patients. 89 TNFα and IL-1β are among a cocktail of cytokines released from macrophages after the immune system is activated. 90 Once released, they act as specific cell-membrane bound receptors to activate a signalling cascade to increase production of pro-inflammatory cytokines, lipid mediators, ROS and cell adhesion molecules. 90, 91 The increased production of cytokines, lipid mediators and cell adhesion molecules facilitates migration of the inflammatory cells into tissues and worsens the lung injury as a result. 90 In an in vitro study, the MSCs secreted cytokine IL-1RA, which dramatically lessens the inflammation effect of TNFα and IL-1β expressed by macrophages. 54 IL-1RA acts as a competitive inhibitor to IL-1β by blocking IL-1β's binding site and the production of TNFα by macrophages. 54 MSCs also release F I G U R E 1 Mechanism of action for MSC therapy against ARDS. MSCs restore damaged lung tissue by secreting paracrine factors, transferring mitochondrial DNA, and liberating microvesicles. Secreted paracrine factors restore the alveolar cells by -first-reducing the effect of apoptosis, oxidation, and inflammation, and -second-restoring the fluid buildup and damaged tissues substances such as TSG-6, IGF-1 and LXA4, which induce antiinflammatory responses in murine acute lung injury models by directly acting on the cells inducing inflammation to undergo phenotypic transition. 57, [61] [62] [63] [64] 92, 93 In addition to abrogating the effect of TNFα, IL-6, and IL-1β, MSCs have also been shown to inhibit recruitment of neutrophils and protein formulation within the inner alveolar space. 94 MSCs can also act to reduce cell attraction and migration as mediators of inflammatory processes, as in lung injury settings. For example, TGFβ1 has an essential role in lung repair and fibroproliferation by promoting collagen synthesis. 95 MSCs showed therapeutic benefit in mice in attenuating acute LPSinduced pulmonary inflammation. 120 In addition, the plasma concentration of sST2 can be used as a diagnostic factor to distinguish ARDS from acute heart failure and serves as a prognostic biomarker to assess the severity of ARDS to determine how supportive treatments and weaning practices should be implemented. [121] [122] [123] In addition to their anti-inflammatory properties, the therapeutic efficacy of MSCs depends on several other factors such as homing, tissue restoration and protective effects against apoptosis and oxidation. Genetic modification can thus serve as an excellent tool to improve the therapeutic benefits of MSCs.

MSCs have shown tropism to injury sites, but they may lose homing receptors after the large-scale expansion needed to produce enough cells for therapeutic doses. 124 MSCs genetically engineered to overexpress the C-X-C motif chemokine receptor 4 (CXCR4) on their cell surface showed improved homing to sites of tissue injury. CXCR4 interacts with its ligand, stromal cell-derived factor-1 (SDF-1), which has elevated expression at sites of tissue injury. [125] [126] [127] [128] Similarly, MSCs that overexpress the E-prostanoid 2 To further enhance lung repair and restore pulmonary functions, genetic modifications involving anti-apoptosis and anti-oxidation pathways, for example overexpression of heme oxygenase-1, are also being extensively investigated. 75, 116, 132 These studies of diverse genetic modifications to MSCs have shown that a single modification can yield multiple benefits and suggest promise of this approach. Given the rapid advance of genetic engineering technology to date, we may expect that the huge capacity of MSCs will allow multiple modifications, raising the possibility of synergistic benefits to treat ARDS and increased numbers of genetically modified MSCs translated to clinical studies. Tables 3 and 4 .

In light of the key role of secretory factors in conferral of therapeutic benefits from MSC therapy, there is increasing interest in studying the therapeutic benefits of MSC-derived extracellular vesicles (MSC-EVs) as compared to MSCs themselves. [125] [126] [127] As MSC-EVs are a cell-free treatment, they offer multiple advantages over cell-based treatments. 133 First, as they are non-nucleated and acellular, they cannot proliferate, and thus, there is minimal risk of tumourigenicity. 134 Second, as they do not express HLA antigens, they pose much lower risks of immunogenicity, and graft-versus-host-disease than their source cells, and thus are safer for allogeneic transplantation as they pose a lower risk of host immunorejection. [135] [136] [137] Third, MSC-EVs are smaller than cells, which allows for better penetration into target tissues. In contrast, because of their larger dimensions cell therapies are restricted from penetrating certain membrane barriers or extravasating from capillaries to key tissues relative to their much smaller secretory vesicles, 137-141 and they carry a higher risk of embolus formation. [142] [143] [144] [145] [146] [147] [148] Furthermore, storage of MSC-EVs does not require cryopreservatives, such as DMSO, which are necessary for long-term storage of MSCs but are detrimental to their viability. In addition, MSC-EVs are less affected by repeated freeze and thaw cycles as compared to MSCs. 136, 143, 149, 150 The secretome of MSCs and other stem cells includes small soluble proteins such as cytokines, chemokines, growth factors, and antiinflammatory factors. 151 incorporate key therapeutic components for delivery. 159, 160 There is ample evidence that extracellular vesicles and their factors derived from a variety of cell sources are also able to directly impart It has been demonstrated for instance that murine bone marrow DCs pulsed with diphtheria toxoid (DT) are induced to generate exosomes promoting a DT-specific immunoglobin response. 164 Treatment with exosomes derived from Toxoplasma gondii antigen There is also evidence of secreted exosomes exhibiting directly antiviral properties through their intrinsic contents. Exosomes secreted by macrophages in response to IFN-a have been demonstrated to utilize Hepatitis A receptors to deliver antiviral substances to hepatocytes. 170 Exosomes isolated from human trophoblasts have also been found to exhibit directly antiviral properties in vitro, associated with miRNA cargoes derived from the chromosome 19 cluster as well as a unique peptide and phospholipid repertoire. 84 Intriguingly, Herpes Simplex 1 (HSV-1) viral microRNAs miR-H28 and miR-H29 transmitted via exosomes have also been found to restrict viral cell-cell transmission via IFN-y upregulation, postulated by the authors to represent a mechanism of limiting viral spread to uninfected cells in favour of maximizing transmission to an alternate host. 171 Exosomes containing the spike S protein derived from other variants of SARS-associated coronavirus (SARS-CoV) have also been found to successfully induce the generation of neutralizing antibodies in a murine model 172 The investigation of the therapeutic benefits of MSC-EVs in comparison to MSCs is a rapidly developing field. As of 5 January 2022, there are nine MSC-EV clinical trials, summarized in Table 5 .

The persistent emergence of novel SARS-Cov-2 variants, and with these fears of novel strains capable of effective vaccine escape and/or heightened virulence, combined with continued strug- 

Data sharing not applicable to this article as no data sets were generated or analyzed during this study.

Christopher D. Cox https://orcid.org/0000-0001-9986-1561

WHO Timeline -COVID-19

Coronavirus Disease

SARS and MERS: recent insights into emerging coronaviruses

Genetic diversity and evolution of SARS-CoV-2

Waning immunity after the BNT162b2 vaccine in Israel

Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months

Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease

The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine-receptor system

Patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries

Acute respiratory distress syndrome

The acute respiratory distress syndrome

The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome

Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; A case-controlled study

Into the looking glass: post-viral syndrome post COVID-19

Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms

Human coronavirus OC43 associated with fatal encephalitis

Microglia are required for protection against lethal coronavirus encephalitis in mice

Case report of transmissible gastroenteritis coronavirus infection associated with small intestine and brain lesions in piglets

Fatal encephalitis associated with coronavirus OC43 in an immunocompromised child

Neuroinvasive potential of human coronavirus OC43: case report of fatal encephalitis in an immunocompromised host

Microglial implications in SARS-CoV-2 infection and COVID-19: Lessons from viral RNA neurotropism and possible relevance to Parkinson's disease

Coronavirus infections-more than just the common cold

Identification of Coronavirus Isolated from a Patient in Korea with COVID-19. Osong Public Health Res Perspect

Changing virulence of the SARS virus: the epidemiological evidence

The severe acute respiratory syndrome

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

Adaptive evolution of MERS-CoV to species variation in DPP4

The architecture of SARS-(:)CoV-2 transcriptome

Roles of Host Gene and Non-coding RNA Expression in Virus Infection

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Acute respiratory distress syndrome: advances in diagnosis and treatment

Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial

Corticosteroids in COVID-19 ARDS: evidence and hope during the pandemic

Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties

Anakinra in COVID-19: important considerations for clinical trials

Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study

Anakinra for severe forms of COVID-19: a cohort study

Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in

A comprehensive review of tocilizumab in covid-19 acute respiratory distress syndrome

Materials-directed differentiation of mesenchymal stem cells for tissue engineering and regeneration

Geometric cues for directing the differentiation of mesenchymal stem cells

Current status of stem cell therapy for sepsis and acute respiratory distress syndrome

Molecular characteristics of bone marrow mesenchymal stem cells, source of regenerative medicine

Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study

Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival

Stem cell therapy in neurodegenerative diseases

Neural stem cell therapy for cancer

Adult human neural stem cell therapeutics: current developmental status and prospect

Human mesenchymal stem cells (hMSCs) target osteosarcoma and promote its growth and pulmonary metastasis

The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells

Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks

Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma

Human mesenchymal stem cells are resistant to cytotoxic and genotoxic effects of cisplatin in vitro

Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury

Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial

In vivo effects of mesenchymal stromal cells in two patients with severe acute respiratory distress syndrome

Acute respiratory distress syndrome: new definition, current and future therapeutic options

Paracrine mechanisms of proliferative, anti-apoptotic and anti-inflammatory effects of mesenchymal stromal cells in models of acute organ injury

Therapeutic potential of mesenchymal stromal cells in the treatment of ARDS

Therapeutic potential of mesenchymal stromal cells for acute respiratory distress syndrome

Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor-α-induced protein 6

Phase-directed therapy: TSG-6 targeted to early inflammation improves bleomycin-injured lungs

Stem cell conditioned medium improves acute lung injury in mice: in vivo evidence for stem cell paracrine action

Human mesenchymal stem (Stromal) cells promote the resolution of acute lung injury in part through Lipoxin A 4

Allogeneic human mesenchymal stem cells restore epithelial protein permeability in cultured human alveolar type II cells by secretion of angiopoietin-1♦

Conditioned media from mesenchymal stromal cells restore sodium transport and preserve epithelial permeability in an in vitro model of acute alveolar injury

Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxininduced acute lung injury in the ex vivo perfused human lung

Clinical grade allogeneic human mesenchymal stem cells restore alveolar fluid clearance in human lungs rejected for transplantation

Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche

Multipotent mesenchymal stromal cells and the innate immune system

Novel cell death program leads to neutrophil extracellular traps

Hypoxia-pretreated human MSCs attenuate acute kidney injury through enhanced angiogenic and antioxidative capacities

Hypoxic preconditioning induces the expression of prosurvival and proangiogenic markers in mesenchymal stem cells

Hypoxia enhances proliferation and tissue formation of human mesenchymal stem cells

Mesenchymal stem cells overexpressing heme oxygenase-1 ameliorate lipopolysaccharide-induced acute lung injury in rats

Adenovirus-mediated expression of the HO-1 protein within MSCs decreased cytotoxicity and inhibited apoptosis induced by oxidative stresses

Nrf-2 overexpression in mesenchymal stem cells reduces oxidative stress-induced apoptosis and cytotoxicity

HIF-1α confers resistance to induced stress in bone marrow-derived mesenchymal stem cells

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan

The acute respiratory distress syndrome: from mechanism to translation

Immunomodulatory potential of human adipose mesenchymal stem cells derived exosomes on in vitro stimulated T cells

Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia

Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: a case report

Isolation of human trophoblastic extracellular vesicles and characterization of their cargo and antiviral activity

Angiopoietin-1 protects the adult vasculature against plasma leakage

Protective role of angiopoietin-1 in endotoxic shock

Opposing effect of angiopoietin-1 on VEGF-mediated disruption of endothelial cell-cell interactions requires activation of PKCβ

Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions

Potential application of mesenchymal stem cells in acute lung injury

The immunopathogenesis of sepsis

Acute pancreatitis induces intrapancreatic tumor necrosis factor gene expression

TNFα-stimulated gene-6 (TSG6) activates macrophage phenotype transition to prevent inflammatory lung injury

Insulin-like growth factor-1 and neuroinflammation

Anti-inflammatory role of mesenchymal stem cells in an acute lung injury mouse model

The role of transforming growth factor β in lung development and disease

Altered expression of small proteoglycans, collagen, and transforming growth factor-beta 1 in developing bleomycin-induced pulmonary fibrosis in rats

Active transforming growth factor-β1 activates the procollagen I promoter in patients with acute lung injury

Interleukin-8 induces the endothelial cell migration through the activation of phosphoinositide 3-Kinase-Rac1/RhoA pathway

Anti-interleukin 8 autoantibody: Interleukin 8 complexes in the acute respiratory distress syndrome

Anti-IL-8 autoantibodies in alveolar fluid from patients with the adult respiratory distress syndrome

Anti-interleukin-8 autoantibodies in patients at risk for acute respiratory distress syndrome

Interleukin 8 and Acute Lung Injury

Recombinant human ACE2: acing out angiotensin II in ARDS therapy

Angiotensin signalling in pulmonary fibrosis

MSCs modified With ACE2 restore endothelial function following LPS challenge by inhibiting the activation of RAS

Mesenchymal stem cells overexpressing angiotensin-converting enzyme 2 rescue lipopolysaccharideinduced lung injury

The pivotal link between ACE2 deficiency and SARS-CoV-2 infection

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor

Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2

Chromatin regulates IL-33 release and extracellular cytokine activity

IL33: roles in allergic inflammation and therapeutic perspectives

Interleukin-33 in tissue homeostasis, injury and inflammation

Interleukin-33 (IL-33): A nuclear cytokine from the IL-1 family

Genetically modified mesenchymal stem cell therapy for acute respiratory distress syndrome

The IL-33/ST2 pathway: therapeutic target and novel biomarker

The ST2/IL-33 axis in immune cells during inflammatory diseases

Inflammation elevated IL-33 originating from the lung mediates inflammation in acute lung injury

Human mesenchymal stem cells overexpressing the IL-33 antagonist soluble IL-1 receptor-like-1 attenuate endotoxin-induced acute lung injury

Plasma concentrations of soluble ST2 and IL-6 are predictive of successful liberation from mechanical ventilation in patients with the acute respiratory distress syndrome

Prognostic and diagnostic value of plasma soluble ST2 concentrations in Acute Respiratory Distress Syndrome

Elevated Plasma Concentrations of Soluble Suppressor of Tumorigenicity-2 (sST2) Accurately Discriminates Acute Respiratory Distress Syndrome from Acute Heart Failure

Mesenchymal stem cells enhance recovery and repair following ventilator-induced lung injury in the rat

Chemokine receptor 7 overexpression promotes mesenchymal stem cell migration and proliferation via secreting Chemokine ligand 12

Mesenchymal stromal cells for treatment of the acute respiratory distress syndrome: the beginning of the story

CXCR4 receptor overexpression in mesenchymal stem cells facilitates treatment of acute lung injury in rats

Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD/SCID mice

PGE2 promotes the migration of mesenchymal stem cells through the activation of FAK and ERK1/2 pathway

E-Prostanoid 2 receptor overexpression promotes mesenchymal stem cell attenuated lung injury

Keratinocyte growth factor promotes epithelial survival and resolution in a human model of lung injury

Paracrine mechanisms of mesenchymal stem cell-based therapy: current status and perspectives

Applying extracellular vesicles based therapeutics in clinical trials-an ISEV position paper

Treatment of experimental necrotizing enterocolitis with stem cell-derived exosomes

Mesenchymal stem cellderived extracellular vesicles attenuate influenza virus-induced acute lung injury in a pig model

Mesenchymal stem cell-derived extracellular vesicles for the treatment of acute respiratory distress syndrome

Exosomes for targeted siRNA delivery across biological barriers

Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes

Exosomes and the blood-brain barrier: implications for neurological diseases

Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio

Peripheral blood exosomes pass blood-brain-barrier and induce glial cell activation

Mesenchymal stem cells-derived extracellular vesicles in acute respiratory distress syndrome: a review of current literature and potential future treatment options

The mesenchymal stem cell secretome: a new paradigm towards cell-free therapeutic mode in regenerative medicine

Mesenchymal stem cell-derived exosomes: applications in cell-free therapy

Concise review: MSC-derived exosomes for cell-free therapy

Mesenchymal stromal cells are more effective than their extracellular vesicles at reducing lung injury regardless of acute respiratory distress syndrome etiology

Neural stem cell derived extracellular vesicles: attributes and prospects for treating neurodegenerative disorders

Chromatographically isolated CD63+ CD81+ extracellular vesicles from mesenchymal stromal cells rescue cognitive impairments after TBI

Effect of Dimethyl Sulfoxide (DMSO) on cryopreservation of Porcine Mesenchymal Stem Cells (pMSCs)

To protect and to preserve: novel preservation strategies for extracellular vesicles

The immunoregulatory activity of mesenchymal stem cells: 'State of Art' and 'Future Avenues'

Exosome-delivered mi-croRNAs modulate the inflammatory response to endotoxin

Mesenchymal stem cells deliver exogenous microRNA-let7c via exosomes to attenuate renal fibrosis

MicroRNA-17-92 cluster in exosomes enhance neuroplasticity and functional recovery after stroke in rats

Adipose tissue macrophage-derived exosomal miRNAs can modulate in vivo and in vitro insulin sensitivity

Mesenchymal stem cell exosome: a novel stem cell-based therapy for cardiovascular disease

Exosomes as a novel way of interneuronal communication

Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery

Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges

Exosomes: therapy delivery tools and biomarkers of diseases

Effective treatment of inflammatory disease models with exosomes derived from dendritic cells genetically modified to express IL-4

Exosome biogenesis and biological function in response to viral infections

Exosomes in pathogen infections: a bridge to deliver molecules and link functions

Exosomes from bone marrow dendritic cells pulsed with diphtheria toxoid preferentially induce type 1 antigenspecific IgG responses in naive recipients in the absence of free antigen

Dimier-Poisson I. A vaccine based on exosomes secreted by a dendritic cell line confers protection against T. gondii infection in syngeneic and allogeneic mice

Mycobacterium tuberculosis synergizes with ATP to induce release of microvesicles and exosomes containing major histocompatibility complex class II molecules capable of antigen presentation

HPV-E7 delivered by engineered exosomes elicits a protective CD8+ T cell-mediated immune response

An exosome-based vaccine platform imparts cytotoxic T lymphocyte immunity against viral antigens

Antigen-loaded exosomes alone induce Th1-type memory through a B cell-dependent mechanism

Exosomes exploit the virus entry machinery and pathway to transmit alpha interferon-induced antiviral activity

Herpes simplex virus 1 MicroRNA miR-H28 exported to uninfected cells in exosomes restricts cell-to-cell virus spread by inducing gamma interferon mRNA

Exosomal vaccines containing the S protein of the SARS coronavirus induce high levels of neutralizing antibodies

Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice

Stem Cell-based therapies for COVID-19-related acute respiratory distress syndrome